NCT00479232View on ClinicalTrials.gov

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

March 31, 2012

Conditions
Leukemia, Myelocytic, Acute Myelodysplastic SyndromesMyelodysplastic Syndromes
Interventions
DRUG

vorinostat

DRUG

decitabine

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00479232 - Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | Biotech Hunter | Biotech Hunter